Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Color-Coded Stem Cells
Researchers develop colour-coding tool for tracking live blood stem cells over time.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
Human Intestines and Functioning Nerves Engineered
The new technology enables the study of human health and advances the goal of regenerative medicine.
Chemical Snapshots Could Lead to Better Engineered Cartilage
Taking "chemical photographs" of the cartilage between joints and comparing it to engineered versions could lead to better implants, say researchers.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
New Model of Lung Regeneration
Scientists have developed a tissue-engineered model of lung and trachea which contains the different cell types found in the repiratory system.
Cause of Inflammation in Diabetes Identified
Suprise discovery has identified a possible trigger of chronic inflammation in diabetes.
Scroll Up
Scroll Down

Custom Optimization of Cell Culture Media for Production of Viral Vaccines
Bookmark and Share

SAFC

Vivalis, a Nantes, France-based biotechnology company,has developed EB66®, a novel cell line derived from duck embryonic stem cells for the cell culture production of viral vaccines. The cell line circumvents the quality and quantity control issues associated with traditional chicken egg andprimary chicken embryo fibroblasts, while eliminating the risk of contamination and the costs associated with serum for growing the fibroblasts. As a result, EB66 cells have become a superior industry alternative for the safe, cost effective manufacturing of viral vaccines. Vivalis offers research and commercial licenses for this cell line to pharmaceutical and biotechnology companies for the production of prophylactic and therapeutic vaccines.

Further Information


Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!